Jin Suxing, Guo Yan, Guo Zijian, Wang Xiaoyong
State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
School of Materials and Chemical Engineering, Henan University of Urban Construction, Pingdingshan 467036, China.
Pharmaceuticals (Basel). 2021 Feb 7;14(2):133. doi: 10.3390/ph14020133.
Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl] (A: Ammonia or amine) stand out as a class of "non-traditional" anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs.
以顺铂为代表的铂类抗癌药物在各种实体瘤的治疗中发挥着重要作用。然而,它们的应用在很大程度上受到耐药性和副作用的影响。人们已经做出了很多努力来规避这些药物的耐药性和一般毒性。在各种各样的设计中,通式为[Pt(3A)Cl](A:氨或胺)的单功能铂(II)配合物作为一类有望克服当前铂类药物缺陷的“非传统”抗癌剂脱颖而出。本综述旨在总结近年来单功能铂(II)配合物的发展情况。它们被分为四类:荧光配合物、光活性配合物、靶向配合物和其他配合物。设计背后的意图要么是可视化细胞分布,要么是减少副作用,要么是提高肿瘤选择性,要么是通过非DNA靶点抑制癌细胞。本综述提供的信息可能会激发研究人员构思出更多具有强大疗效的创新配合物,以摆脱铂类抗癌药物的缺点。